Patents by Inventor David H. Beach
David H. Beach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7691632Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein.Type: GrantFiled: August 20, 2008Date of Patent: April 6, 2010Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Publication number: 20090193531Abstract: The present invention provides methods for attenuating gene expression in a cell using gene-targeted double stranded RNA (dsRNA). The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene).Type: ApplicationFiled: May 16, 2008Publication date: July 30, 2009Applicant: Cold Spring Harbor LaboratoryInventors: David H. Beach, Emily Bernstein, Amy Caudy, Scott Hammond, Gregory Hannon
-
Publication number: 20090170098Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein.Type: ApplicationFiled: August 20, 2008Publication date: July 2, 2009Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Patent number: 7550561Abstract: The present invention relates to the discovery in eukaryotic cells, particularly human cells, a novel polypeptide of 16 kDa (hereinafter “p16INK4” or “p16”) can function as an inhibitor of cell cycle progression, and therefore ultimately of cell growth, and that similar to the role of p21 and p53, the p16 protein may function coordinately with the cell cycle regulatory protein, retinoblastoma (Rb).Type: GrantFiled: April 14, 1994Date of Patent: June 23, 2009Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Patent number: 7425617Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins.Type: GrantFiled: January 30, 1998Date of Patent: September 16, 2008Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Patent number: 7005258Abstract: Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2 are described. As a result of this work, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases or through alteration of the interaction of components of MPF. More specifically, the invention relates to inhibiting transcription or translation of mammalian CDC25A genes using oligonucleotides.Type: GrantFiled: October 30, 2000Date of Patent: February 28, 2006Assignee: The National Institutes of HealthInventors: David H. Beach, Konstantin Galaktionov
-
Publication number: 20040086884Abstract: The present invention provides methods for attenuating gene expression in a cell using gene-targeted double stranded RNA (dsRNA). The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene).Type: ApplicationFiled: January 24, 2003Publication date: May 6, 2004Applicants: Genetica, Inc., Cold Spring Harbor LaboratoryInventors: David H. Beach, Emily Bernstein, Amy Caudy, Scott Hammond, Gregory J. Hannon, Patrick J. Paddison, Douglas Conklin
-
Publication number: 20030100489Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.Type: ApplicationFiled: September 4, 2001Publication date: May 29, 2003Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Patent number: 6566054Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of mutant cyclin dependent kinase (CDK) proteins. These proteins fail to bind to CDK-inhibitory proteins and thus lead to aberrant cell growth. Herein, screening assays are described to identify CDK mutant proteins and the uses of these mutant proteins as tumor vaccines is described.Type: GrantFiled: August 30, 1996Date of Patent: May 20, 2003Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Manuel Serrano
-
Patent number: 6495526Abstract: The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.Type: GrantFiled: July 29, 1997Date of Patent: December 17, 2002Assignee: GPC Biotech, Inc.Inventors: Jeno Gyuris, Lou Lamphere, David H. Beach
-
Patent number: 6486131Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.Type: GrantFiled: January 30, 1998Date of Patent: November 26, 2002Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Publication number: 20020082392Abstract: The present invention reldates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.Type: ApplicationFiled: January 30, 1998Publication date: June 27, 2002Inventors: DAVID H. BEACH, DOUGLAS J. DEMETRICK, MANUEL SERRANO, GREGORY J. HANNON
-
Publication number: 20020068706Abstract: The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.Type: ApplicationFiled: July 29, 1997Publication date: June 6, 2002Inventors: JENO GYURIS, LOU LAMPHERE, DAVID H. BEACH
-
Publication number: 20020025305Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.Type: ApplicationFiled: January 30, 1998Publication date: February 28, 2002Inventors: DAVID H. BEACH, DOUGLAS J. DEMETRICK, MANUEL SERRANO, GREGORY J. HANNON
-
Patent number: 6331390Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins is characterized by four ankyrin repeats and the ability to bind to a cyclin dependent kinase (CDK). The family includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB).Type: GrantFiled: June 30, 1995Date of Patent: December 18, 2001Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Patent number: 6322975Abstract: The present invention makes available assays and reagents for identifying agents which can be used to modulate at least one proliferation, differentiation and cell death by apoptosis.Type: GrantFiled: January 15, 1999Date of Patent: November 27, 2001Inventors: David H. Beach, Konstantin Galaktionov
-
Publication number: 20010044102Abstract: The present invention makes available assays and reagents for identifying agents which can be used to modulate at least one proliferation, differentiation and cell death by apoptosis.Type: ApplicationFiled: January 15, 1999Publication date: November 22, 2001Inventors: DAVID H. BEACH, KONSTANTIN GALAKTIONOV
-
Patent number: 6255071Abstract: The present invention relates to methods and compositions for the elucidation of mammalian gene function. Specifically, the present invention relates to methods and compositions for improved mammalian complementation screening, functional inactivation of specific essential or non-essential mammalian genes, and identification of mammalian genes which are modulated in response to specific stimuli. In particular, the compositions of the present invention include, but are not limited to, replication-deficient retroviral vectors, libraries comprising such vectors, retroviral particles produced by such vectors in conjunction with retroviral packaging cell lines, integrated provirus sequences derived from the retroviral particles of the invention and circularized provirus sequences which have been excised from the integrated provirus sequences of the invention. The compositions of the present invention further include novel retroviral packaging cell lines.Type: GrantFiled: March 19, 1997Date of Patent: July 3, 2001Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Gregory J. Hannon, Douglas Conklin, Peiqing Sun
-
Patent number: 6211334Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.Type: GrantFiled: November 29, 1994Date of Patent: April 3, 2001Assignee: Cold Spring HarborInventors: David H. Beach, Manuel Serrano, Gregory J. Hannon
-
Patent number: 6156876Abstract: A novel class of cyclins, referred to as D-type cyclins, of mammalian origin, particularly human origin, DNA and RNA encoding the novel cyclins, and a method of identifying other D-type and non-D type cyclins. Also disclosed are a method of detecting an increased level of a D-type cyclin and a method of inhibiting cell division by interfering with formation of the protein kinase-D type cyclin complex essential for cell cycle start.Type: GrantFiled: October 18, 1994Date of Patent: December 5, 2000Assignee: Cold Spring Harbor LaboratoryInventor: David H. Beach